Abeona TherapeuticsABEO
ABEO
About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Employees: 136
0
Funds holding %
of 7,435 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
470% more call options, than puts
Call options by funds: $9.96M | Put options by funds: $1.75M
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
133% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 18
40% more capital invested
Capital invested by funds: $141M [Q1] → $198M (+$56.7M) [Q2]
32% more funds holding
Funds holding: 71 [Q1] → 94 (+23) [Q2]
6.97% more ownership
Funds ownership: 61.14% [Q1] → 68.12% (+6.97%) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
184%
upside
Avg. target
$20
184%
upside
High target
$20
184%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 184%upside $20 | Buy Reiterated | 18 Aug 2025 |
Oppenheimer Andreas Argyrides | 184%upside $20 | Outperform Maintained | 15 Aug 2025 |
Financial journalist opinion
Based on 5 articles about ABEO published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Brian Kevany - Senior VP, CTO & CSO Gregory Gin - Vice President of Investor Relations & Corporate Communications Joseph Walter Vazzano - Chief Financial Officer Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Vishwas Seshadri - President, CEO & Director Conference Call Participants James Francis Molloy - Alliance Global Partners, Research Division Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Operator Good Day everyone, and welcome to the Abeona Therapeutics Second Quarter 2025 Conference Call.
Positive
Seeking Alpha
1 week ago
Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn
The FDA's approval and commercial launch of Abeona Therapeutics Inc.'s Zevaskyn for RDEB, plus $155M PRV sale, provides strong financial runway for company for two years. AIM AAV204 capsid platform and ABO-503 gene therapy offer differentiated potential in rare eye disorders, with key catalysts in 2025-2026. ABEO expansion opportunities exist via licensing deals, notably with Beacon Therapeutics, and broader application of the AIM capsid library towards other indications.
Neutral
GlobeNewsWire
1 week ago
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
Neutral
GlobeNewsWire
3 weeks ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
4 weeks ago
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partnership with Abeona Therapeutics Inc. (Nasdaq: ABEO) in the successful pre-and-post launch commercialization of ZEVASKYN™, an FDA-approved cell-based gene therapy.
Neutral
GlobeNewsWire
1 month ago
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
- Lucile Packard Children's Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - - ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of the newest Qualified Treatment Center (QTC) for FDA-approved ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy, an outcome of a decade of research by Abeona and two decades of research at Stanford Medicine, where the technology originated, will be used to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Neutral
PRNewsWire
1 month ago
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
MINNEAPOLIS , July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout clinical development, Simple Western enabled precise identification and quantification of Collagen VII, a complex therapeutic target critical to ZEVASKYN's potency, supporting lot release testing for the viral vector and the cell therapy in a GMP setting.
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Cash resources totaled approximately $225 million as of June 30, 2025 Cash resources totaled approximately $225 million as of June 30, 2025
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties
Neutral
GlobeNewsWire
1 month ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™